Descovy

RSS

emtricitabine / tenofovir alafenamide

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Descovy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Descovy.

For practical information about using Descovy, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 14/11/2022

Authorisation details

Product details
Name
Descovy
Agency product number
EMEA/H/C/004094
Active substance
  • emtricitabine
  • tenofovir alafenamide
International non-proprietary name (INN) or common name
  • emtricitabine
  • tenofovir alafenamide
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR17
Publication details
Marketing-authorisation holder
Gilead Sciences Ireland UC
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
21/04/2016
Contact address

IDA Business & Technology Park
Carrigtohill
County Cork
T45 DP77
Ireland

Product information

10/11/2022 Descovy - EMEA/H/C/004094 - WS2331

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

Assessment history

Related content

How useful was this page?

Add your rating
Average
3 ratings